New osteoporosis drug copycat tested in healthy women
NCT ID NCT07497503
First seen Mar 29, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This early-stage trial is testing whether a new drug called B-3E07 works the same as the approved osteoporosis drug Forsteo. 48 healthy adult women will receive a single injection of each drug in random order. The main goal is to compare how the body absorbs and processes the drugs, and to check for any safety issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Veritus Research
RECRUITINGBayswater, Victoria, 3153, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
B-3E07 (a proposed biosimilar of teriparatide) and Forsteo (teriparatide)
What this could lead to
If B-3E07 is shown to be similar to Forsteo, it could become a more affordable option for treating osteoporosis.
What could go wrong
This is an early phase 1 study in only 48 healthy volunteers, not patients. It only measures drug levels and safety, not whether the drug actually treats disease. Biosimilars can sometimes differ in effectiveness or side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.